Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,618.00
Bid: 1,615.00
Ask: 1,616.00
Change: 1.50 (0.09%)
Spread: 1.00 (0.062%)
Open: 1,619.50
High: 1,622.50
Low: 1,606.00
Prev. Close: 1,616.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

European gas inventories back to 10-year average

Wed, 17th Aug 2022 12:19

EUROPEAN GAS INVENTORIES BACK TO 10-YEAR AVERAGE (1117 GMT)

As well as watching trading screens, market players are keeping one eye on European gas supplies as a key metric when weighing up the economic outlook.

According to UBS analysts, European gas storage usage reached its 10-year average at the beginning of August.

As of August 13, storage was 74% full - above last year's level of 61%. At this rate, by the end of October storage levels could be near to 90%, the analysts said in a note.

We can thank liquid natural gas imports for that.

"Imports (of LNG) were up 110% y/y in July and are up 61% y/y YTD which helps to offset low volumes from Russia," they said in a note.

On the other hand, Russian exports have continued to decline.

"In 1H Aug Gazprom exports to Europe stood at ~2.6bcm, down 64% y/y, close to the July daily average."

The analysts said they expect LNG imports in Europe to remain close to first half levels in the second half, but that "risks are to the downside", with potentially more competition from Asian buyers and risk of supply disruptions.

"And these come at a high price, TTF (front-month) approaching €250/MWh today."

STOXX 600: NOT MUCH TO EXPECT FROM EARNINGS NOW (0926 GMT)

The better-than-expected Q2 earnings season, along with a weaker euro, was an essential driver of the summer rally which has lifted the pan-European STOXX 600 over 10% since the June lows.

But as you see can below from the latest Refinitiv I/B/E/S estimates, profit growth is expected to reverse into an earnings recession in 2023:

Moving forward, European stocks, still down over 9% year-to-date, will therefore not likely be able to count on earnings to rebound further this year.

"Q2 earnings have not been the disaster some had predicted, but mixed guidance, high inventories and rising margin pressures offer little comfort", Barclays strategists argued in a note.

So with little to expect from earnings growth, multiples need to expand for the rally to keep on going.

"As slowing growth caps the upside to FY estimates, at best, the bull case for equities relies on renewed P/E expansion", they wrote, calling such a re-rating "elusive".

Then again, as they show in this chart, the low level of European price-to-earnings ratios seems to suggest that there is potentially some upside:

(Julien Ponthus)

STOXX SET FOR SIXTH CONSECUTIVE DAY OF GAINS (0753 GMT)

European shares are into their sixth consecutive day of gains, with the STOXX 600 opening 0.3% higher as markets continue to brush off fears of an energy crisis and recession on the continent.

The financial services sector is leading gains with a 0.88% rise, while healthcare and basic resources are ringing in at the bottom, down 0.22% and 0.35% respectively.

Shares in Uniper are falling 8.2% and are at the bottom of the STOXX 600, unsurprising given the company just reported a hefty 12 billion euro loss in the first half .

Shares in GSK are down 2.1% but stayed above recent lows after the plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial agreed to drop his case .

At the top of the index is Swiss laboratory instruments maker Tecan Group, surging 12% after a H1 beat and raising its FY sales outlook.

MORE DOOM AND GLOOM LOOMS FOR EUROPE (0640 GMT)

Europeans will be hoping Wednesday’s economic data will provide some respite after a string of negative headlines, but past form suggests they’d be foolish to bet too much on it.

They might even be better off taking a punt on depressing figures, as at least their winnings might provide some small cheer if the bad news arrives.

British consumer price inflation jumped to 10.1% in July, its highest since February 1982, up from an annual rate of 9.4% in June, intensifying the squeeze on households, official figures showed on Wednesday

That’s not good news for British workers who saw earnings for the second quarter adjusted for inflation fall by 4.1%, the biggest drop since records began in 2001, according to data released on Tuesday.

The final reading for Euro zone Q2 GDP is also due on Wednesday, and while preliminary data showed faster than expected growth, even then economists said it might be the economy's last hurrah.

If data from down under offers any clues, they aren’t great.

Earlier on Wednesday New Zealand’s Central Bank signalled a more hawkish tightening path over coming months to restrain stubbornly high inflation, even as it delivered its seventh straight interest rate hike, and Australian wage growth missed forecasts and lagged badly behind inflation.

The kiwi dollar initially climbed on the news before giving up its gains, though the Aussie held onto its losses.

Asian shares eked out small gains in morning trading, following overnight gains on Wall Street, where economic data is less depressing.

Japan was in the lead with the Nikkei up 1%, while MSCI’s broadest index of shares outside Japan rose just 0.2%.

Key developments that could influence markets on Wednesday:

UK Jul CPI, Jul PPI

Euro zone Q2 flash employment, Q2 GDP

US Jul retail sales

US 20-year Treasury auction

Fed Reserve releases minutes from July policy meeting at 1800 GMT

New Zealand's central bank meeting and press conference.

European earnings: Swiss Life, Carlsberg, Uniper

US earnings: Lowe’s, Target, Cisco

(Alun John)

WHAT ECONOMIC GLOOM?: (0629 GMT)

European shares look set for their sixth consecutive day of rises, with futures contracts signalling increases of 0.3% as they track U.S. shares which posted gains on Tuesday after some strong showings from major retailers.

U.S. retail sales data will give a further insight today but in the meantime there are some not so pretty earnings coming out of Europe to contend with.

Danish brewer Carlsberg reported Q2 sales below expectations, while Germany's Uniper, which secured a 15 billion euro bailout last month, reported a net loss of more than 12 billion euros ($12.2 billion) for the first half.

Better news is coming from insurer Swiss Life which has increased its half year net profit by 4%.

On the data front, UK CPI was seen rising to the highest level since 1982, up to 10.1% in July from 9.4% in June.

(Lucy Raitano)

More News
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.